The Economics of Cancer Care

May 31 from 12:30 PM-5:00 PM and June 1 from 7:30 AM-11:00 AM
McCormick Place, Room S102

Seminar Description

Oncology professionals are practicing in an increasingly complex economic landscape, with pressures from several different areas. There is much discussion regarding treatment costs, impacting both practice sustainability and patient financial burden, as well as how to reward therapeutic innovation while managing development costs. Innovative reimbursement, coverage, and treatment models provide lessons learned and new best practices, and the base of data in this area is rapidly expanding. All of this coupled with clinical trial costs and trends in overall cancer treatment spending have resulted in wealth of information to examine and assimilate into individual research and practice decisions. This seminar provides learners with relevant information regarding all of these topics, so they can make better-informed decisions in their relations with patients, payers and others.

Go to to view session slides on your personal device in real time, take notes on slides, pose questions to faculty, and participate in audience polling. Link will be live when the session begins on Thursday, May 31.

Seminar Agenda

Note: Session faculty will be added to the agenda below as presenters are confirmed.

Day 1: Thursday, May 31, 2018: 12:30 PM - 5:00 PM

12:30 PM - 1:00 PM Lunch
1:00 PM - 2:55 PM 

Session 1: Financial Toxicity—How Costs Negatively Impact Patients and What Can Be Done About It?


Robin Yabroff, PhD—Chair
American Cancer Society
Cost and Financial Hardship


Cara McDermott, PhD, PharmD
Fred Hutchinson Cancer Research Center
The Role of De-implementation in End-of-Life Care


Yousuf Zafar, MD, MHS
Duke University Medical Center
Do Patients Want to Discuss Cost with Their Oncologists?


Andrew Schorr
Patient Power, LLC
The Patient Advocate Perspective on Financial Toxicity and Cost


Panel Question and Answer 

2:55 PM - 3:05 PM Break
3:05 PM - 5:00 PM

Session 2: All About the Drugs
Elad Sharon, MD, MPH—Chair

National Cancer Institute


Juliette Cubanski, PhD, MPP, MPH
Kaiser Family Foundation
Insurance and the Cost of Drugs for Patients


Murray L. Aitken, MBA
IQVIA Institute for Human Data Science
A Global Perspective on Drug Reimbursement


Joshua Bilenker, MD
Loxo Oncology
Discussions of Market Regulations and the Effects on Global Capital Markets


Stacie Dusetzina, PhD
Vanderbilt University Medical Center
An Overview of the National Academy's Recommendation on Drug Access


Panel Question and Answer


Day 2: Friday, June 1, 2018: 7:00 AM - 11:00 AM

7:00 AM - 7:30 AM Breakfast
7:30 AM - 8:50 AM

Session 3: The International Experience: Can We Learn from Each Other?

Richard Sullivan, MD, PhD—Chair
King's Health Partners Cancer Center


Andre Ilbawi, MD
World Health Organization
The Utilization of Costing Tools


Richard Sullivan, MD, PhD
King's Health Partners Cancer Center
International Approaches to Affordability in Cancer Control


Christopher Booth, MD
Queen's University
Improving Accessibility and Quality of Cancer Care in India


Ophira Ginsburg, MD
New York University Langone Medical Center
Best Practices to Reduce Health Inequities for Under-served Women With Cancer


Panel Discussion and Question and Answer

8:50 AM - 9:00 AM Break
9:00 AM - 11:00 AM

Session 4: Payment Models and Innovations in Cancer Care Delivery

Rena M. Conti, PhD—Chair 
University of Chicago


Rena M. Conti, PhD 
University of Chicago
340B, Reimbursement Reform, and Changes to Oncology


James Gajewski, MD
Oregon Society of Medical Oncology
Risk Adjustment Methods


John Colmers, MPH
Johns Hopkins University
Maryland's All-Payer Model


Nancy L. Keating, MD, MPH
Harvard Medical School
An Evaluator's Perspective on the Oncology Care Model


Panel Question and Answer


Seminar Committee

View Seminar Committee Disclosures

Elad Sharon, MD, MPH (Chair)​
National Cancer Institute

Rena M. Conti, PhD​
University of Chicago

John Vernon Cox, DO, FACP, FASCO, MBA
Parkland Health System/UTSW

Stacie Dusetzina, PhD
Vanderbilt University

Richard Sullivan, PhD
King's Health Partners Cancer Center

Robin Yabroff, PhD
American Cancer Society


 "Jointly Accredited Provider, Interprofessional Continuing Education"

In support of improving patient care, the American Society of Clinical Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians

The American Society of Clinical Oncology Designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA/NCCPA Credit Designation Statement - Physician Assistants

Physician Assistants may claim a maximum of 7.25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. 

All non-physician attendees are welcome to submit a request for a Certificate of Participation, which may enable non-physicians to apply their meeting participation toward re-licensure. Please note, however, that all final decisions regarding certificate acceptance will be made by the licensing organization to which the certificate is submitted. 

Target Audience

The 2018 Economics of Cancer Care Seminar is designed for the cancer care team; credit is offered for physicians, but all are encouraged to participate, as they may be able to apply for credit through their own licensing organization.

Learning Objectives

Upon participation in this activity, attendees will be able to: 

  • Discuss financial toxicity, the role of cost of care at end-of-life, and the patient perspective on the cost of care to improve these discussions with patients in practice
  • Evaluate models of controlling and perspectives on drug costs to be able to address the effects of high drug costs on patient care
  • Analyze international models of affordability of cancer care for incorporation across practice settings, as applicable
  • Review payment models and innovations in cancer care delivery to apply in practice, as appropriate

Disclaimer/Unlabeled Usage Statement         

The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions and adverse effects.

Commercial Support

ASCO and Conquer Cancer gratefully awknowledge the following companies for their support of the 2018 The Economics of Cancer Care Seminar:

Abbvie Amgen Astellas